loader
Please Wait
Applying Filters...
menu
    • menu

    List of Written Confirmation(s) issued for disodium [3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate Active Pharmaceutical Ingredient (API)

    Client Email Product
    2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Aug 2024: Otsuka buys Jnana, Lilly’s market cap gains by over US$ 108 bn post new guidance

    Stock Recap
    #PipelineProspector

    Menu

    disodium;[3-amino-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 103,862Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    27/04/2020 Cipla
    India
    		 Cipla Limited WC-0144A3 Pamidronate sodium USP 2019-10-01 2022-09-08 Plot. D-7 MIDC, Kurkumbh, Dist. Pune-413802
    27/04/2020 Sun Pharmaceutical Industries Limited
    India
    		 M/s. Sun Pharmaceuticals Industries Ltd. WC-0159 Disodium Pamidronate (USP/EP/BP) 2022-06-08 2025-07-25 A-7/A-8, MIDC, Ahmednagar-414 111, Maharashtra State